Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
248 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015', provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Wet (Neovascular / Exudative) Macular Degeneration and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Wet (Neovascular / Exudative) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Wet (Neovascular / Exudative) Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Wet (Neovascular / Exudative) Macular Degeneration Overview 10 Therapeutics Development 11 Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview 11 Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis 12 Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies 13 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies 21 Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development 26 Aciont Inc. 26 Allergan Plc 27 Amakem NV 28 Apellis Pharmaceuticals, Inc. 29 Apexigen, Inc. 30 Applied Genetic Technologies Corporation 31 Avalanche Biotechnologies, Inc. 32 Benitec Biopharma Limited 33 BIOCAD 34 Boehringer Ingelheim GmbH 35 Charlesson LLC. 36 Chong Kun Dang Pharmaceutical Corp. 37 Circadian Technologies Limited 38 Clanotech AB 39 Clearside BioMedical, Inc. 40 Daiichi Sankyo Company, Limited 41 Eleven Biotherapeutics Inc. 42 Exonate Limited 43 F. Hoffmann-La Roche Ltd. 44 Formycon AG 45 GTx, Inc. 46 iCo Therapeutics Inc. 47 Icon Bioscience, Inc. 48 Kala Pharmaceuticals, Inc. 49 Mabion SA 50 Mitotech S.A. 51 Neurotech Pharmaceuticals, Inc. 52 Novartis AG 53 Ocular Therapeutix, Inc. 54 Ohr Pharmaceutical Inc. 55 Ophthotech Corp. 56 Oxford BioMedica Plc 57 PanOptica, Inc. 58 Pfenex Inc. 59 Pfizer Inc. 60 Quark Pharmaceuticals, Inc. 61 Regeneron Pharmaceuticals, Inc. 62 RegenxBio Inc. 63 RXi Pharmaceuticals Corporation 64 Santen Pharmaceutical Co., Ltd. 65 Sanwa Kagaku Kenkyusho Co., Ltd. 66 TRACON Pharmaceuticals, Inc. 67 TWi Pharmaceuticals, Inc. 68 Tyrogenex, Inc. 69 Xbrane Bioscience AB 70 Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics Assessment 71 Assessment by Monotherapy Products 71 Assessment by Combination Products 72 Assessment by Target 73 Assessment by Mechanism of Action 76 Assessment by Route of Administration 78 Assessment by Molecule Type 80 Drug Profiles 82 (aflibercept + nesvacumab) - Drug Profile 82 (aflibercept + rinucumab) - Drug Profile 83 abicipar pegol - Drug Profile 84 AC-301 - Drug Profile 87 aflibercept - Drug Profile 88 aflibercept biosimilar - Drug Profile 91 AGN-151200 - Drug Profile 92 ALG-1001 - Drug Profile 93 AMA-0428 - Drug Profile 95 APL-2 - Drug Profile 96 APX-003 - Drug Profile 98 APX-3330 - Drug Profile 99 AVA-101 - Drug Profile 101 AVA-201 - Drug Profile 103 avacincaptad pegol sodium - Drug Profile 104 bertilimumab - Drug Profile 106 Beta-LGND2 - Drug Profile 108 bevacizumab biosimilar - Drug Profile 110 BI-144807 - Drug Profile 111 brolucizumab - Drug Profile 112 C-16Y - Drug Profile 114 CLT-005 - Drug Profile 116 CLT-28643 - Drug Profile 117 cyclosporine - Drug Profile 118 DE-120 - Drug Profile 119 DNX-214 - Drug Profile 120 Doxarubicin Pegylated - Drug Profile 121 Drug for Age Related Macular Degeneration - Drug Profile 122 DS-7080 - Drug Profile 123 ENV-705 - Drug Profile 124 GB-101 - Drug Profile 125 GB-102 - Drug Profile 126 Gene Therapy for Wet Age-related Macular Degeneration - Drug Profile 127 HMR-59 - Drug Profile 128 K-106 - Drug Profile 129 LHA-510 - Drug Profile 130 LMG-324 - Drug Profile 131 Monoclonal Antibody to Inhibit VEGF for Wet Macular Degeneration - Drug Profile 132 nesvacumab - Drug Profile 133 NT-503 - Drug Profile 135 NT-506 - Drug Profile 136 OCU-200 - Drug Profile 137 OLX-301 - Drug Profile 138 ONL-1204 - Drug Profile 139 OXB-201 - Drug Profile 140 PAN-90806 - Drug Profile 141 pegpleranib sodium - Drug Profile 143 PF-05206388 - Drug Profile 145 PF-655 - Drug Profile 146 plastoquinone decyl triphenylphosphonium bromide - Drug Profile 149 Protein to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 151 ranibizumab - Drug Profile 152 ranibizumab biosimilar - Drug Profile 156 ranibizumab biosimilar - Drug Profile 157 ranibizumab biosimilar - Drug Profile 158 ranibizumab biosimilar - Drug Profile 160 ranibizumab biosimilar - Drug Profile 161 ranibizumab biosimilar - Drug Profile 162 Recombinant Protein for Age Related Macular Degeneration - Drug Profile 163 Recombinant Proteins to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 164 RG-7716 - Drug Profile 165 RGX-314 - Drug Profile 166 RXI-109 - Drug Profile 167 SK-1011 - Drug Profile 169 Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile 170 Small Molecules to Inhibit VEGF and PDGF for Wet AMD - Drug Profile 171 Small Molecules to Inhibit VEGF for Wet AMD - Drug Profile 172 SPHINX-31 - Drug Profile 173 squalamine lactate - Drug Profile 174 tesidolumab - Drug Profile 177 TRC-105 - Drug Profile 179 triamcinolone acetonide - Drug Profile 182 TT-211 - Drug Profile 183 TT-231 - Drug Profile 184 VGX-300 - Drug Profile 186 X-82 - Drug Profile 188 Wet (Neovascular / Exudative) Macular Degeneration - Recent Pipeline Updates 190 Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects 229 Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products 232 Wet (Neovascular / Exudative) Macular Degeneration - Product Development Milestones 233 Featured News & Press Releases 233 Appendix 242 Methodology 242 Coverage 242 Secondary Research 242 Primary Research 242 Expert Panel Validation 242 Contact Us 242 Disclaimer 243
List of Tables
Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H2 2015 16 Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis, H2 2015 17 Number of Products under Development by Companies, H2 2015 19 Number of Products under Development by Companies, H2 2015 (Contd..1) 20 Number of Products under Development by Companies, H2 2015 (Contd..2) 21 Number of Products under Development by Companies, H2 2015 (Contd..3) 22 Comparative Analysis by Late Stage Development, H2 2015 23 Comparative Analysis by Clinical Stage Development, H2 2015 24 Comparative Analysis by Early Stage Development, H2 2015 25 Products under Development by Companies, H2 2015 26 Products under Development by Companies, H2 2015 (Contd..1) 27 Products under Development by Companies, H2 2015 (Contd..2) 28 Products under Development by Companies, H2 2015 (Contd..3) 29 Products under Development by Companies, H2 2015 (Contd..4) 30 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Aciont Inc., H2 2015 31 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Allergan Plc, H2 2015 32 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Amakem NV, H2 2015 33 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Apellis Pharmaceuticals, Inc., H2 2015 34 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Apexigen, Inc., H2 2015 35 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Applied Genetic Technologies Corporation, H2 2015 36 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Avalanche Biotechnologies, Inc., H2 2015 37 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Benitec Biopharma Limited, H2 2015 38 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by BIOCAD, H2 2015 39 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Boehringer Ingelheim GmbH, H2 2015 40 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Charlesson LLC., H2 2015 41 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 42 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Circadian Technologies Limited, H2 2015 43 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clanotech AB, H2 2015 44 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clearside BioMedical, Inc., H2 2015 45 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 46 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc., H2 2015 47 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Exonate Limited, H2 2015 48 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 49 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Formycon AG, H2 2015 50 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by GTx, Inc., H2 2015 51 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by iCo Therapeutics Inc., H2 2015 52 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H2 2015 53 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kala Pharmaceuticals, Inc., H2 2015 54 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mabion SA, H2 2015 55 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mitotech S.A., H2 2015 56 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Neurotech Pharmaceuticals, Inc., H2 2015 57 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Novartis AG, H2 2015 58 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ocular Therapeutix, Inc., H2 2015 59 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ohr Pharmaceutical Inc., H2 2015 60 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ophthotech Corp., H2 2015 61 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Oxford BioMedica Plc, H2 2015 62 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by PanOptica, Inc., H2 2015 63 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfenex Inc., H2 2015 64 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfizer Inc., H2 2015 65 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Quark Pharmaceuticals, Inc., H2 2015 66 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 67 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by RegenxBio Inc., H2 2015 68 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by RXi Pharmaceuticals Corporation, H2 2015 69 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2015 70 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2015 71 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TRACON Pharmaceuticals, Inc., H2 2015 72 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TWi Pharmaceuticals, Inc., H2 2015 73 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Tyrogenex, Inc., H2 2015 74 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Xbrane Bioscience AB, H2 2015 75 Assessment by Monotherapy Products, H2 2015 76 Assessment by Combination Products, H2 2015 77 Number of Products by Stage and Target, H2 2015 79 Number of Products by Stage and Mechanism of Action, H2 2015 82 Number of Products by Stage and Route of Administration, H2 2015 84 Number of Products by Stage and Molecule Type, H2 2015 86 Wet (Neovascular / Exudative) Macular Degeneration Therapeutics - Recent Pipeline Updates, H2 2015 195 Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects, H2 2015 234 Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..1), H2 2015 235 Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..2), H2 2015 236 Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products, H2 2015 237
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
